Autopsy report · NCT04685499
Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease
Cause of deathSlow enrollment
“This study was terminated due to low participant enrollment.”
Life of this trial
- Registered 4 months before it started.
- Ran for about 1 year 1 month before it stopped.
- 1 participant enrolled.
- Results were posted on the registry 7 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Weill Medical College of Cornell University
- Sponsor type
- University, hospital or other
- Conditions
- Head and Neck Squamous Cell Carcinoma With Inoperable Recurrent or Progressive Disease
- Interventions
- OBP-301; Pembrolizumab
- Participants
- 1
- Sites
- 1
- Countries
- United States
Trials that died the same way
- A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
“The study was terminated due to low enrollment.” - BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
“Study was terminated due to low enrollment.” - The Effect of Blended Sensor Efficiency on Relieving the Heart's Inability to Increase Its Rate During Exercise
“The study was terminated due to poor enrollment.” - MIRACLE EF Clinical Study
“The study was terminated early due to low enrollment.” - The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5
“This study was prematurely terminated due to low enrollment”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.